Symeres, a mid-sized, transatlantic contract research and development organisation (CRO/CDMO) specialising in small-molecule drug discovery and development, has acquired DGr Pharma for an undisclosed amount. This corporate acquisition sees Symeres expanding its service offerings by purchasing a company known for its early-phase drug development consultancy. Symeres operates with headquarters in the Netherlands and locations across Europe and the United States, bringing over 30 years of industry experience to its biotech clients.
DGr Pharma provides consultancy support in early phase drug development, focusing on critical areas such as Pharmacokinetics (PK), Clinical Pharmacology, Chemistry, Manufacturing & Control (CMC), Regulatory Affairs, and IT support. The company also offers stand-alone non-compartmental analyses using Phoenix WinNonlin. With an extensive track record spanning over 25 years, DGr Pharma facilitates fast and high-quality drug development processes for pharmaceutical and biotech companies through its consultancy and contract research services, leveraging staff with significant industrial and regulatory expertise.
This acquisition is strategically significant for Symeres, as it integrates DGr Pharma’s specialized early-phase drug development consultancy and regulatory expertise directly into Symeres’ comprehensive CRO/CDMO framework. The addition of DGr Pharma's services, particularly in PK, CMC, and regulatory guidance, enhances Symeres' ability to offer a more complete suite of solutions to its clients from discovery through early development. The synergy is expected to streamline the drug development process for biotech and pharmaceutical companies, providing them with integrated support across a broader spectrum of their research and development needs.
The combined entity is poised to offer clients a more holistic and efficient partner for their small-molecule drug development programs. By bringing DGr Pharma's deep consultancy knowledge and regulatory experience under the Symeres umbrella, the acquisition is anticipated to strengthen Symeres' position in the contract research market, enabling it to deliver integrated services that accelerate client projects and navigate complex development pathways more effectively.